🔗 Share this article The United States and United Kingdom Reach Duty-Free Pact on Pharmaceuticals. Representative image of drug trade. Britain and America have hammered out a significant trade agreement that will preserve zero import taxes on British medicine products being sold in the American market. Key Provisions of the Accord As part of the deal, the UK has committed to boost spending on medicines through the NHS. This pledge ensures that duties on these key exports will be held at zero for a timeframe of the next three years. This deal is in response to earlier threats to significantly raise tariffs on branded drug imports, with figures mentioned up to one hundred percent. "This deal with the United Kingdom reinforces the international landscape for new treatments and introduces long-overdue balance to transatlantic drug exports," an announcement noted. Trade Impact Drugs constitute one of the Britain's largest exports to the United States, which is easily the largest destination for large companies like GSK and AstraZeneca. Export figures show that in the 12 months to the end of September, the UK shipped medicines valued at £11.1bn to the US. This amount represented a significant portion of all goods exports in that period. "This guarantee secures jobs, boosts capital expenditure and facilitates the UK to become a international leader for medical research," the Business and Trade Secretary remarked. Specific UK Commitments The deal includes several key commitments from the UK: Revised Affordability Limit: The UK will raise the price threshold at which it considers new medicines to be unaffordable by twenty-five percent. Higher Drug Budget: There is a target to double total public funding on treatments from 0.3 percent of GDP to 0.6 percent over the coming ten years. Rebate Cap: The amount manufacturers must refund to the NHS to prevent overspending will be restricted at fifteen percent. Previously, repayments were more than twenty percent. Industry Background This agreement follows a ongoing tension between the drug companies and the British authorities over spending levels and regulatory access. These tensions were heightened by arguments that American customers were paying several times more for the same drugs than people in the Britain and the EU. Recently, several major pharmaceutical investments in the UK have been delayed or abandoned, while multi-billion-dollar investments have been directed toward US facilities. A senior figure acknowledged that the NHS had to increase expenditure on medicines, noting that its budget allocation on drugs had declined as a percentage of its total funding over the previous ten-year period.
Representative image of drug trade. Britain and America have hammered out a significant trade agreement that will preserve zero import taxes on British medicine products being sold in the American market. Key Provisions of the Accord As part of the deal, the UK has committed to boost spending on medicines through the NHS. This pledge ensures that duties on these key exports will be held at zero for a timeframe of the next three years. This deal is in response to earlier threats to significantly raise tariffs on branded drug imports, with figures mentioned up to one hundred percent. "This deal with the United Kingdom reinforces the international landscape for new treatments and introduces long-overdue balance to transatlantic drug exports," an announcement noted. Trade Impact Drugs constitute one of the Britain's largest exports to the United States, which is easily the largest destination for large companies like GSK and AstraZeneca. Export figures show that in the 12 months to the end of September, the UK shipped medicines valued at £11.1bn to the US. This amount represented a significant portion of all goods exports in that period. "This guarantee secures jobs, boosts capital expenditure and facilitates the UK to become a international leader for medical research," the Business and Trade Secretary remarked. Specific UK Commitments The deal includes several key commitments from the UK: Revised Affordability Limit: The UK will raise the price threshold at which it considers new medicines to be unaffordable by twenty-five percent. Higher Drug Budget: There is a target to double total public funding on treatments from 0.3 percent of GDP to 0.6 percent over the coming ten years. Rebate Cap: The amount manufacturers must refund to the NHS to prevent overspending will be restricted at fifteen percent. Previously, repayments were more than twenty percent. Industry Background This agreement follows a ongoing tension between the drug companies and the British authorities over spending levels and regulatory access. These tensions were heightened by arguments that American customers were paying several times more for the same drugs than people in the Britain and the EU. Recently, several major pharmaceutical investments in the UK have been delayed or abandoned, while multi-billion-dollar investments have been directed toward US facilities. A senior figure acknowledged that the NHS had to increase expenditure on medicines, noting that its budget allocation on drugs had declined as a percentage of its total funding over the previous ten-year period.